Show simple item record

dc.contributor.authorPower, Rachel F*
dc.contributor.authorHynes, Brian G*
dc.contributor.authorMoran, Darragh*
dc.contributor.authorYagoub, Hatim*
dc.contributor.authorKiernan, Gary*
dc.contributor.authorRuggiero, Nicholas J*
dc.contributor.authorKiernan, Thomas J*
dc.date.accessioned2013-05-21T14:29:34Z
dc.date.available2013-05-21T14:29:34Z
dc.date.issued2012-10
dc.identifier.citationModern antiplatelet agents in coronary artery disease. 2012, 10 (10):1261-72 Expert Rev Cardiovasc Theren_GB
dc.identifier.issn1744-8344
dc.identifier.pmid23190065
dc.identifier.doi10.1586/erc.12.127
dc.identifier.urihttp://hdl.handle.net/10147/292584
dc.description.abstractDual antiplatelet therapy is well recognized in the prevention of thrombotic complications of acute coronary syndrome and percutaneous coronary interventions. Despite clinical benefits of aspirin and clopidogrel therapy, a number of limitations curtail their efficacy: slow onset of action, variability in platelet inhibitory response and potential drug-drug interactions. Furthermore, the single platelet-activation pathway targeted by these agents allows continued platelet activation via other pathways, ensuring incomplete protection against ischemic events, thus, underscoring the need for alternate antiplatelet treatment strategies. A number of novel antiplatelet agents are currently in advance development and many have established superior effects on platelet inhibition, clinical outcomes and safety profile than clopidogrel in high-risk patients. The aim of this review is to provide an overview of the current status of P2Y12 receptor inhibition and PAR-1 antagonists in determining a future strategy for individualized antiplatelet therapy.
dc.language.isoenen
dc.rightsArchived with thanks to Expert review of cardiovascular therapyen_GB
dc.subject.meshAnimals
dc.subject.meshCoronary Artery Disease
dc.subject.meshDrug Design
dc.subject.meshDrug Therapy, Combination
dc.subject.meshHumans
dc.subject.meshIndividualized Medicine
dc.subject.meshPlatelet Aggregation Inhibitors
dc.subject.meshPurinergic P2Y Receptor Antagonists
dc.subject.meshReceptor, PAR-1
dc.subject.meshReceptors, Purinergic P2Y12
dc.titleModern antiplatelet agents in coronary artery disease.en_GB
dc.contributor.departmentDepartment of Interventional Cardiology, Cork University Hospital, University College Cork School of Medicine, Cork, Ireland.en_GB
dc.identifier.journalExpert review of cardiovascular therapyen_GB
dc.description.provinceMunsteren
html.description.abstractDual antiplatelet therapy is well recognized in the prevention of thrombotic complications of acute coronary syndrome and percutaneous coronary interventions. Despite clinical benefits of aspirin and clopidogrel therapy, a number of limitations curtail their efficacy: slow onset of action, variability in platelet inhibitory response and potential drug-drug interactions. Furthermore, the single platelet-activation pathway targeted by these agents allows continued platelet activation via other pathways, ensuring incomplete protection against ischemic events, thus, underscoring the need for alternate antiplatelet treatment strategies. A number of novel antiplatelet agents are currently in advance development and many have established superior effects on platelet inhibition, clinical outcomes and safety profile than clopidogrel in high-risk patients. The aim of this review is to provide an overview of the current status of P2Y12 receptor inhibition and PAR-1 antagonists in determining a future strategy for individualized antiplatelet therapy.


This item appears in the following Collection(s)

Show simple item record